PET Imaging

Tracer-focused PET modules — same lineup as the PET panel in Radiopharmaceuticals, split into routine clinical use vs Phase 3 / investigational.

Current clinical use

FDA-cleared / routine PET tracers in US clinical practice.

Coming soon

Amyloid PET

Brain β-amyloid plaque imaging.

Placeholder page
Coming soon

Bone PET (NaF)

F-18 sodium fluoride osteoblastic bone PET.

Placeholder page
Coming soon

Cardiac PET

Perfusion (Rb-82, N-13) and FDG viability/inflammation.

Placeholder page
Coming soon

DOTATATE PET

Somatostatin receptor PET for NETs and theranostics.

Placeholder page
Coming soon

FDG PET

Glucose metabolism — oncology, infection, brain, viability.

Placeholder page
Coming soon

FES PET

Estrogen receptor imaging in breast cancer.

Placeholder page
Coming soon

Fluciclovine (Axumin)

Amino-acid PET for prostate biochemical recurrence.

Placeholder page
Coming soon

PSMA PET

Ga-68 and F-18 PSMA ligands for prostate imaging.

Placeholder page

Clinical trials / investigational

Phase 3 or investigational — not FDA-approved routine care.

In trials

FAPI PET

Phase 3 FAP stroma imaging — GI oncology trial space.

Placeholder page
In trials

I-124 evuzamitide PET

Phase 3 cardiac amyloid PET peptide — REVEAL.

Placeholder page
In trials

Cu-64 bisPSMA PET

Phase 3 SAR-bisPSMA — BCR prostate imaging.

Placeholder page
In trials

F-18 mFBG PET

Phase 3 PET MIBG analog for neuroblastoma.

Placeholder page
In trials

O-15 water PET

Quantitative blood-flow PET — investigational / select clinical use.

Placeholder page